Alnylam's Onpattro: Not Following FDA Guidance Amplifies Clinical Meaningfulness Concerns

 
• By Sarah Karlin-Smith
image of the heart (organ)
FDA advisors will vote on a supplemental indication for Onpattro for the treatment of ATTR cardiomyopathy 13 September. • Source: Shutterstock

More from United States

More from North America